The great potential of FGF2 inhibitors as antineoplastic therapeutics lies in the fact that a number of tumor types are intrinsically dependent on the FGF/FGFR signaling, that induces angiogenesis, exerts pleiotropic effects on both the tumor cells and the surrounding stroma and mediates resistance to antiangiogenc and targeted therapies1, 2, 6, 8. Here, FGF2 is linked to neoplasm.